Thursday, April 24, 2008

Strides Arcolab Receives 2 ANDA Approvals for Ondansetron Injection USP, 2 mg/ml (20 ml vials) and 2 mg/ml (2 ml vials)

April 24, 2008-Strides Arcolab today announced receipt of 2 ANDA approvals for Ondansetron Injection USP, 2 mg/ml (20 ml vials) and 2 mg/ml (2 ml vials).

The product is licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn, Inc and Strides Arcolab Limited.

Mr.Arun Kumar - Vice Chairman and Group CEO of Strides Arcolab stated:


"These approvals reflect yet another significant milestone for the Akorn-Strides partnership which now has approvals for five sterile injectable products and plans for commercialization are underway. "

No comments: